Table 1.
Clinical characteristics of FTLD patients included in the study
| FTLD total N (%)c |
FTLD with C9orf72 HRE N (%)c |
FTLD without C9orf72 HRE N (%)c |
|
|---|---|---|---|
| Total number (N) | 98a | 27a | 58a |
| CBA analysis (plasma) | 50 (51%) | 22 (81%) | 28 (48%) |
| Simoa (sera) | 91 (93%) | 26 (96%) | 52 (90%) |
| hs-CRP | 44 (45%) | 19 (70%) | 24 (41%) |
| Gender (F/M, %) | 53/47% | 52/48% | 57/43% |
| Mean ageb ± SD | 64.7 ± 8.8 | 61.2 ± 9.3 | 66.2 ± 8.0 |
| bvFTD (N) | 71 (72%) | 20 (74%) | 39 (67%) |
| PPA (N) | 21 (21%) | 5 (19%) | 15 (26%) |
| nfvPPA (N) | 17 (17%) | 5 (19%) | 11 (19%) |
| svPPA (N) | 4 (4%) | 0 (0%) | 4 (7%) |
| FTLD-MND (N) | 6 (6%) | 2 (7%) | 4 (7%) |
| FTLD with Parkinsonism (N)d | 23 (23%) | 8 (30%) | 13 (22%) |
| FTLD with psychotic symptoms (N)d | 34 (35%) | 10 (37%) | 18 (31%) |
aFTLD total group includes overall 13 patients without known C9orf72 HRE status
bAge is calculated from the date of the blood sample
cPercentages are calculated from the total number of cases in each column
dOut of the FTLD patients with Parkinsonism (N = 23), 17 patients had Parkinsonism symptoms at the time of the blood sample and FTLD diagnosis and 6 patients developed Parkinsonism after the blood sample and FTLD diagnosis. All of the patients with psychotic symptoms (N = 34) had their first psychotic symptoms before the blood sample and FTLD diagnosis